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sion within conceptual framework of Andersen’s Behavioral Model was used to 
examine the predisposing, enabling and need characteristics associated with antide-
pressant use. RESULTS: The overall prevalence of antidepressant use was found to 
be 46.22% (95%CI, 45.16–47.27). The most prescribed class of antidepressants was 
SSRIs (67.29%), followed by serotonin modulators (10.05%), SNRIs (6.02%), TCAs 
(5.06%) and MAO inhibitors (0.02%). Citalopram (28%) was the highest prescribed 
individual antidepressant followed by mirtazapine (22.05%). Among the predisposing 
characteristics, age, race, and marital status were signiﬁcantly associated with antide-
pressant drug use. Enabling factors like Medicare or Medicaid payment source and 
facility bed capacity predicted antidepressant use. Among need characteristics, likeli-
hood of receiving antidepressant prescription decreased with increased dependence in 
decision making ability and out of bed mobility. Also presence of depressed mood 
indicators, history of falls and fractures, and an increase in number of medications 
prescribed had positive association with antidepressant prescription. CONCLU-
SIONS: Nearly half of elderly nursing home residents received antidepressants. Pre-
disposing, need, and enabling factors played important roles in use of antidepressants. 
Overall, the study ﬁndings suggest that antidepressant treatment is highly prevalent 
in nursing homes possibly due to increased recognition of symptoms in the elderly 
population.
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OBJECTIVES: Psychotropic use in nursing homes has been a concern due to extensive 
misuse of these agents in the elderly. Very little is known about recent national level 
utilization in nursing homes especially after the introduction of newer psychotropic 
agents. Therefore, this study examined psychotropic drug use patterns among elderly 
nursing home residents at the national level by using the 2004 National Nursing Home 
Survey (NNHS) data. METHODS: This study involved retrospective, cross-sectional 
analysis of the 2004 NNHS. The study sample included patients aged 65 years or 
older. Psychotropic drugs were classiﬁed as antidepressants, sedative/hypnotics, anti-
anxiety, antipsychotics, and stimulants based on existing literature. Psychotropic 
polypharmacy was deﬁned as concomitant use of two or more psychotropic drugs. 
SAS survey procedures were used for descriptive domain analysis and to calculate 95% 
Conﬁdence Intervals (CI) of weighted estimates. RESULTS: According to the 2004 
NNHS, an estimated 0.83 (95% CI, 0.82–0.85) million elderly nursing home residents 
received at least one psychotropic medication for an overall prevalence of 63.18% 
(95% CI, 62.16—64.21), while 25.85% (95% CI: 24.92%–26.77%) received two or 
more psychotropic medications. Antidepressant agents (46.22%, 95% CI: 45.16%–
47.27%) were the most prescribed psychotropic drug class followed by antipsychotics 
agents (24.84%, 95% CI: 23.92%–25.76%). Psychotropic polypharmacy within the 
antidepressant class was highest (5.92%, 95% CI: 5.43%–6.41%) followed by anti-
psychotics (1.17%, 95% CI: 0.94%–1.39%). CONCLUSIONS: Nearly two-third 
elderly nursing home residents received psychotropic medications, while more than 
one in four residents were receiving two or more psychotropic drugs. With increasing 
concerns of inappropriate psychotropic drug use, there is a strong need to monitor 
their usage in this vulnerable population.
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OBJECTIVES: To examine the inﬂuence of inexpensive generic programs on prescrip-
tion medication acquisition behavior of patients. METHODS: Cross-sectional survey 
of 200 consecutive patients during regularly scheduled appointments to an adult 
general medicine clinic. Questions were asked to determine the type of pharmacy 
patients obtained their current prescription medication from; whether they were aware 
of focused programs selling generic medication for a reduced cost; whether they had 
ﬁlled a prescription recently using a reduced cost generic program, and if they did, 
whether they had other medications ﬁlled at the same pharmacy. Demographic data 
was also obtained. Data were analyzed using descriptive statistics. Respondents were 
categorized as having ﬁlled a prescription using an inexpensive generic program or 
not. Differences in demographics and medication-related variables between the two 
groups were analyzed using Student’s t-test for continuous variables or Chi-squared 
test for categorical variables. P value of less than 0.05 were considered statistically 
signiﬁcant. RESULTS: Only 5% of respondents (11 of 210) used an inexpensive 
generic program to ﬁll at least one of their prescriptions. Characteristics of patients 
who tended to use the generic programs included greater number of prescriptions, 
lower household income, no prescription insurance, and be of female gender. The 
study is limited in generalizability due to the small number of respondents in the group 
who had a prescription ﬁlled by an inexpensive generic program. CONCLUSIONS: 
This small study provides encouraging data to support the development of a larger 
study of the inﬂuence of the generic programs on patient behavior in regards to deci-
sion of where to obtain prescriptions. Larger studies may also attempt to determine 
whether these programs improve access to medications that patients may have had 
trouble affording before their inception.
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OBJECTIVES: Duloxetine is approved for the treatment of major depressive disorder 
(MDD) and general anxiety disorder (GAD), and for the management of diabetic 
peripheral neuropathic pain (DPNP) and ﬁbromyalgia. It has also demonstrated sig-
niﬁcant pain relief among patients with chronic lower back pain (CLBP) and osteo-
arthritis. For patients with each of these conditions, this study assessed pain medication 
use prior to duloxetine initiation. METHODS: A large, US administrative claims 
database was used to identify commercially-insured duloxetine initiators during 2007 
and 2008 who had any of the 6 medical conditions mentioned above during the 12 
months prior to duloxetine initiation. Initiation was deﬁned as no duloxetine pill 
coverage in the previous 90 days. Utilization of pain-related medications including 
antidepressants, anticonvulsants, opioids, non-steroidal anti-inﬂammatory drugs 
(NSAIDs), and muscle relaxants, was assessed over the 6 or 12 months prior to 
duloxetine initiation, respectively. RESULTS: The study identiﬁed 44,838 duloxetine 
initiators in 2008, with 13,809, 3,289, 1,501, 8,731, 7,871, and 18,987 in the MDD, 
GAD, DPNP, ﬁbromyalgia, osteoarthritis, and CLBP groups, respectively. Antidepres-
sant use was high across all conditions over the 12 months prior to duloxetine initia-
tion, especially among patients with MDD (83.5%) or GAD (78.8%). Anticonvulsant 
utilization was highest in DPNP (63.4%) and ﬁbromyalgia (55.0%), lowest in GAD 
(39.3%), but similar between other groups (ranged 42.3–48.9%). Opioid use varied 
greatly across groups (55.1–82.8%), with the highest (lowest) use among CLBP (GAD) 
patients. GAD patients had the lowest NSAID use (32.1%), while osteoarthritis 
patients had the highest utilization (59.4%). The use of muscle relaxants ranged 
between 28.2% (GAD and DPNP) and 54.5% (CLBP). Pain medication use in the 
prior 6 months showed similar patterns, but was in general about 10–15 percentage 
points lower. Results for 2007 initiators were similar. CONCLUSIONS: Patients used 
several types of pain medications prior to initiating duloxetine across disease states.
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OBJECTIVES: Over 700 new molecular entities (NMEs) were approved between 1980 
and 2008 in the U.S. Although a small percentage of these products will inevitably be 
discontinued, concerns over safety are purported to be the main impetus for discon-
tinuing a drug from the market. In this study, a trend analysis was performed to 
examine the pattern of discontinued NMEs approved by the FDA from 1980 to 2008. 
METHODS: Data were derived from the FDA, Federal Register, Micromedex, 
Medline, Lexis-Nexis, journal articles, governmental web pages and other publicly 
available documents. A drug was considered discontinued if it was deleted from the 
2009 version of the FDA’s Orange book: Approved Drug Products with Therapeutic 
Equivalence Evaluations. Descriptive statistics, chi-square tests, logistic regression, and 
survival analysis were performed. For the Kaplan-Meier survival curves, drug that 
were not discontinued during the study time-period were censored. RESULTS: A total 
of 703 NMEs were approved during the study period. Of the 101 NMEs that were 
discontinued, 29 were due to safety concerns. Controlling for other factors, the odds 
(OR:2.53; 95% CI:1.42–4.55) of a drug being discontinued for reasons other than 
safety and efﬁcacy were signiﬁcantly higher than the odds of being discontinued for 
safety reasons (p < 0.05). Compared to other therapeutic classes, anti-infective drugs 
were more likely to be discontinued (p < 0.05). Results from the Kaplan-Meier survival 
analysis revealed the estimated probability of discontinuing a NME from the market 
over a 20 year time period was 15.0%. CONCLUSIONS: Survival analysis provided 
useful estimates for the probability of discontinuation. Safety concerns for NMEs were 
not the foremost reasons for drug discontinuation; rather ﬁnancial reasons may con-
tribute to a larger portion of discontinuations. However, additional studies are needed 
to assess how probabilities for drug discontinuation are inﬂuenced by decision-making 
entities regarding drug approval, drug development and innovation, and drug policy.
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OBJECTIVES: With US health care reform proposing to extend Medicare coverage 
to individuals between the ages of 55–64, the pressure for coverage will dramatically 
increase. We examined demand ﬁve drug markets—cholesterol, diabetes, depression, 
hypertension and pain—for this age group compared to others. We also compared the 
cost burden under Medicare Part D compared payers to highlight the demand for 
more affordable drugs from individuals that are not yet eligible for Medicare coverage. 
METHODS: For each drug market, total prescriptions (TRx), new patient prescrip-
tions (NPRx), and average prescription size were obtained for each of the age groups 
analyzed (≤18, 19–35, 36–54, 55–64, ≥65). For each drug market, average out of 
pocket cost (OPC) was also compared between Medicare beneﬁciaries and other 
patients. Data were collected for eight quarters, spanning November 2007 to Novem-
